RA Capital Management Leads $45M Series A Financing for PepGen’s Next-Generation Oligonucleotide Platform Targeting Duchenne Muscular Dystrophy and Other Rare Neuromuscular and Cardiac Diseases

from Venture Capital Access Online: Latest Venture Capital and Private Equity News https://ift.tt/2W1iiEp
via IFTTT